Literature DB >> 25486577

Neuroprotective kynurenine metabolite indices are abnormally reduced and positively associated with hippocampal and amygdalar volume in bipolar disorder.

Jonathan Savitz1, Robert Dantzer2, Brent E Wurfel3, Teresa A Victor3, Bart N Ford3, Jerzy Bodurka4, P S F Bellgowan5, T Kent Teague6, Wayne C Drevets7.   

Abstract

Inflammation-related changes in the concentrations of kynurenine-pathway metabolites occur in depression secondary to medical conditions but have not been well characterized in primary bipolar disorder (BD), with contradictory results potentially attributable to the presence or absence of psychosis and/or medication effects. In contrast, reductions in hippocampal and amygdalar volume that theoretically reflect dendritic atrophy occurring in the context of a neurotoxic process are commonly reported in unmedicated BD patients. Here we tested whether the concentrations of putatively neuroprotective (kynurenic acid, KynA) and neurotoxic (3-hydroxy-kynurenine, 3HK and quinolinic acid, QA) kynurenine-pathway metabolites were altered in primary BD and whether these metabolites were associated with hippocampal and amygdalar volume. Twenty-five moderately-to-severely depressed unmedicated subjects and 38 moderately-to-severely depressed medicated subjects who met DSM-IV-TR criteria for BD, as well as 48 healthy controls (HCs) completed a structural MRI scan and provided a blood sample for kynurenine metabolite analysis, performed using high performance liquid chromatography with tandem mass spectrometry. Gray matter volumes were measured with the automated segmentation software, FreeSurfer. A putative neuroprotective index, KynA/QA, was significantly lower in the BD subjects relative to the HCs, a finding that was unrelated to current treatment with medication or a prior history of psychosis. Further, another putative neuroprotective index, KynA/3HK was positively associated with hippocampal volume in the BD group after controlling for age, sex, body mass index (BMI), and intracranial volume (ICV). Kyn/3HK was significantly associated with total amygdalar volume in the BD group, but after controlling for age, sex, BMI, but not ICV, this association was reduced to a trend. In addition, Kyn/3HK was positively associated with amygdalar volume in the HCs although the association was no longer significant after accounting for the effects of age, sex, and BMI. The results raise the possibility that BD-associated abnormalities in kynurenine metabolism may impact the structure of the hippocampus and amygdala, highlighting a pathway through which inflammation may exert neuropathological effects in the context of depression.
Copyright © 2014 Elsevier Ltd. All rights reserved.

Entities:  

Keywords:  Bipolar disorder; Hippocampus; Inflammation; Kynurenine; Magnetic resonance imaging; Quinolinic acid

Mesh:

Substances:

Year:  2014        PMID: 25486577      PMCID: PMC4297593          DOI: 10.1016/j.psyneuen.2014.11.015

Source DB:  PubMed          Journal:  Psychoneuroendocrinology        ISSN: 0306-4530            Impact factor:   4.905


  47 in total

1.  Hydrogen peroxide-mediated neuronal cell death induced by an endogenous neurotoxin, 3-hydroxykynurenine.

Authors:  S Okuda; N Nishiyama; H Saito; H Katsuki
Journal:  Proc Natl Acad Sci U S A       Date:  1996-10-29       Impact factor: 11.205

2.  Glial fibrillary acidic protein mRNA levels in the cingulate cortex of individuals with depression, bipolar disorder and schizophrenia.

Authors:  M J Webster; J O'Grady; J E Kleinman; C S Weickert
Journal:  Neuroscience       Date:  2005       Impact factor: 3.590

3.  Cellular changes in the postmortem hippocampus in major depression.

Authors:  Craig A Stockmeier; Gouri J Mahajan; Lisa C Konick; James C Overholser; George J Jurjus; Herbert Y Meltzer; Harry B M Uylings; Lee Friedman; Grazyna Rajkowska
Journal:  Biol Psychiatry       Date:  2004-11-01       Impact factor: 13.382

4.  Kynurenic acid antagonises responses to NMDA via an action at the strychnine-insensitive glycine receptor.

Authors:  P J Birch; C J Grossman; A G Hayes
Journal:  Eur J Pharmacol       Date:  1988-09-01       Impact factor: 4.432

5.  Similarities and differences in the neuronal death processes activated by 3OH-kynurenine and quinolinic acid.

Authors:  A Chiarugi; E Meli; F Moroni
Journal:  J Neurochem       Date:  2001-06       Impact factor: 5.372

6.  Studies on the neuroprotective action of kynurenine mono-oxygenase inhibitors in post-ischemic brain damage.

Authors:  Flavio Moroni; Raffaella Carpenedo; Andrea Cozzi; Elena Meli; Alberto Chiarugi; Domenico E Pellegrini-Giampietro
Journal:  Adv Exp Med Biol       Date:  2003       Impact factor: 2.622

7.  Effect of excess extracellular glutamate on dendrite growth from cerebral cortical neurons at 3 days in vitro: Involvement of NMDA receptors.

Authors:  Hubert Monnerie; Shalini Shashidhara; Peter D Le Roux
Journal:  J Neurosci Res       Date:  2003-12-01       Impact factor: 4.164

8.  Impact of social status and antidepressant treatment on neurogenesis in the baboon hippocampus.

Authors:  Melody V Wu; Jul Lea Shamy; Gillinder Bedi; Chien-Wen J Choi; Melanie M Wall; Victoria Arango; Maura Boldrini; Richard W Foltin; René Hen
Journal:  Neuropsychopharmacology       Date:  2014-02-12       Impact factor: 7.853

9.  Decreased level of kynurenic acid in cerebrospinal fluid of relapsing-onset multiple sclerosis patients.

Authors:  Konrad Rejdak; Halina Bartosik-Psujek; Beata Dobosz; Tomasz Kocki; Pawelz Grieb; Gavin Giovannoni; Waldemar A Turski; Zbigniew Stelmasiak
Journal:  Neurosci Lett       Date:  2002-10-04       Impact factor: 3.046

10.  Kynurenine pathway abnormalities in Parkinson's disease.

Authors:  T Ogawa; W R Matson; M F Beal; R H Myers; E D Bird; P Milbury; S Saso
Journal:  Neurology       Date:  1992-09       Impact factor: 9.910

View more
  41 in total

1.  Sleep disturbance and kynurenine metabolism in depression.

Authors:  Hyong Jin Cho; Jonathan Savitz; Robert Dantzer; T Kent Teague; Wayne C Drevets; Michael R Irwin
Journal:  J Psychosom Res       Date:  2017-05-22       Impact factor: 3.006

2.  Poisoning with Soman, an Organophosphorus Nerve Agent, Alters Fecal Bacterial Biota and Urine Metabolites: a Case for Novel Signatures for Asymptomatic Nerve Agent Exposure.

Authors:  Derese Getnet; Aarti Gautam; Raina Kumar; Allison Hoke; Amrita K Cheema; Franco Rossetti; Caroline R Schultz; Rasha Hammamieh; Lucille A Lumley; Marti Jett
Journal:  Appl Environ Microbiol       Date:  2018-10-17       Impact factor: 4.792

Review 3.  Kynurenine pathway dysfunction in the pathophysiology and treatment of depression: Evidences from animal and human studies.

Authors:  Gislaine Z Réus; Karen Jansen; Stephanie Titus; André F Carvalho; Vilma Gabbay; João Quevedo
Journal:  J Psychiatr Res       Date:  2015-05-19       Impact factor: 4.791

Review 4.  Role of Adiposity-Driven Inflammation in Depressive Morbidity.

Authors:  Lucile Capuron; Julie Lasselin; Nathalie Castanon
Journal:  Neuropsychopharmacology       Date:  2016-07-11       Impact factor: 7.853

5.  Role of Kynurenine pathway and its metabolites in mood disorders: A systematic review and meta-analysis of clinical studies.

Authors:  Danilo Arnone; Smita Saraykar; Haitham Salem; Antonio L Teixeira; Robert Dantzer; Sudhakar Selvaraj
Journal:  Neurosci Biobehav Rev       Date:  2018-06-22       Impact factor: 8.989

6.  Reduction of kynurenic acid to quinolinic acid ratio in both the depressed and remitted phases of major depressive disorder.

Authors:  Jonathan Savitz; Wayne C Drevets; Brent E Wurfel; Bart N Ford; Patrick S F Bellgowan; Teresa A Victor; Jerzy Bodurka; T Kent Teague; Robert Dantzer
Journal:  Brain Behav Immun       Date:  2015-02-14       Impact factor: 7.217

7.  A pilot resting-state functional connectivity study of the kynurenine pathway in adolescents with depression and healthy controls.

Authors:  Samuel J DeWitt; Kailyn A Bradley; Na Lin; Chunli Yu; Vilma Gabbay
Journal:  J Affect Disord       Date:  2017-11-20       Impact factor: 4.839

8.  Kynurenic acid is reduced in females and oral contraceptive users: Implications for depression.

Authors:  Timothy B Meier; Wayne C Drevets; T Kent Teague; Brent E Wurfel; Sven C Mueller; Jerzy Bodurka; Robert Dantzer; Jonathan Savitz
Journal:  Brain Behav Immun       Date:  2017-09-01       Impact factor: 7.217

9.  Smaller Dentate Gyrus and CA2 and CA3 Volumes Are Associated with Kynurenine Metabolites in Collegiate Football Athletes.

Authors:  Timothy B Meier; Jonathan Savitz; Rashmi Singh; T Kent Teague; Patrick S F Bellgowan
Journal:  J Neurotrauma       Date:  2016-01-13       Impact factor: 5.269

10.  Kynurenine pathway metabolites are associated with hippocampal activity during autobiographical memory recall in patients with depression.

Authors:  Kymberly D Young; Wayne C Drevets; Robert Dantzer; T Kent Teague; Jerzy Bodurka; Jonathan Savitz
Journal:  Brain Behav Immun       Date:  2016-04-29       Impact factor: 7.217

View more

北京卡尤迪生物科技股份有限公司 © 2022-2023.